top of page

"Medical Affairs Consulting, Inspiring Impactful Change in Health Equity"

Please Visit Us At Our New Site: EquityBridgeConsulting.Com

  • Medical affairs outsourcing companies are essential for non-promotional expert scientific and medical information to healthcare professionals, participating in pre- and post launch activities, identifying insights from key opinion leaders, engaging with patient advocacy groups, advisory boards, etc.

  • Field based medical science liaisons (MSLs) attend conferences, provide training, develop materials, and develop strategy. 

Adalynn E. Harris, PhD, MPH, MHA
Founder and President

• HBCU Graduate: Morehouse School of Medicine; NC A&T State University

• Other Graduate Degrees: UNC-Chapel Hill; George Washington University

• Post-Doctoral Fellowship: Fellowship In Research and Science Teaching (FIRST)

• Medical Affairs Experience: 15+ years in pharmaceutical industry

• Career Experience: Clinical Trial/Scientific Support; Health Disparities; Strategy Design and Implementation; Advisory Board Facilitation

President in Red Jacket 2023.jpg
Blue Background


•  Equity Bridge ConsultingSM provides scientific support for all the for inclusion of persons who have historically been un- or under-represented in research/clinical trials arena. ​


This is accomplished via:

•  Medical affairs-based activities including (1) strategic interactions; (2) diversity education (i.e. the need for diverse inclusion in basic research, clinical trial and public health areas) to the pharmaceutical, academic and community institution; (3)HEOR assistance for subsidiaries and sites (academic and community) specifically regarding minority issues; and (4) Assistance with Clinical development activities.


​•  Global outreach to include sub-Saharan Africa and persons from the African diaspora. 

Abstract Linear Background


Abstract Linear Background



•Provide drivers of innovation with medical affairs outsourcing

•Filling gaps in medical affairs capabilities 

•Assistance with Clinical Trial Accrual for minority groups


Marginalized Communities and Patient Advocacy Groups

•Scientific Updates on Drugs/Diagnostics

•Discussions on Clinical Trial Data

•Relaying Drug and Diagnostics Development

•Education regarding Adverse Events/ Safety


Clinical Research Workforce

Diversity in Workforce Development Strategy

•Minority physicians and scientists

•Diversification built in all levels of clinical trials

•Special Attention to HBCUs/MSIs

bottom of page